SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third parties. Conduit entered into a $2.65 million loan note with Nirland on August 6, 202 ...

Group 1 - Conduit Pharmaceuticals (NASDAQ:CDT) stock experienced an increase following a shareholder update revealing that Nirland Limited holds a 14.8% stake in the company [1][2] - Nirland Limited's stake consists of 12.5 million shares and warrants for an additional 2 million shares, based on the company's outstanding shares of 98,004,699 [2] - The stake was acquired through a Senior Secured Promissory Note as part of Conduit Pharmaceuticals' merger agreement with Murphy Canyon Acquisition Corp [2] Group 2 - Following the news, CDT stock saw heavy trading with over 72 million shares changing hands, significantly higher than the daily average of about 10 million shares [3] - As of Wednesday morning, CDT stock rose by 11.7%, although it remains down 96.7% since the beginning of the year [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT T O SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41245 CONDUIT PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) | --- | --- | |----------------------- ...

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656 AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Condu ...

Core Viewpoint - Conduit Pharmaceuticals has received a new patent for its HK-4 Glucokinase Activator, which targets autoimmune diseases, leading to a significant increase in its stock price [2][7]. Company Developments - The company has secured an Australian patent for its lead asset, which is expected to enhance its intellectual property portfolio and future out-licensing opportunities [2][7]. - Conduit Pharmaceuticals plans to pursue similar patents in other regions, including the U.S., Europe, and Japan, utilizing the Patent Prosecution Highway (PPHH) [3]. Market Reaction - Following the patent approval, Conduit Pharmaceuticals' stock (CDT) experienced a trading surge, with over 41.7 million shares traded, significantly higher than its average daily volume of approximately 317,000 shares [7]. - As of Tuesday morning, CDT stock rose by 73%, although it had previously declined by 94.9% year-to-date before this news [8].

The Company is enrolled to participate in the Patent Prosecution Highway (PPH), a program to fast-track patent examination in major jurisdictions including the U.S., Europe and Japan. Since IP Australia has allowed patent application 2022384750, Conduit believes it is more likely to receive subsequent approvals in other markets. Patents in these major countries are the most sought after and valuable patents for marketed drug products, providing up to 20 years of patent protection. Conduit Pharmaceuticals (N ...

SHENZHEN, China, June 27, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) ("CDT"), a leading provider of waste treatment systems and services throughout China, announces the signing of a strategic cooperation framework agreement with a local high-tech company in Fujian Province. The collaboration leverages the complementary strengths of both parties, with CDT contributing its government relations, brand advantages, and expertise in waste treatment solutions, ...

SHENZHEN, China, June 18, 2024 (GLOBE NEWSWIRE) -- CDT Environmental Technology Investment Holdings Limited (NASDAQ: CDTG) ("CDT"), a leading provider of waste treatment systems and services throughout China, announces the signing of a strategic cooperation agreement with a subsidiary of a large stateowned construction group in China. The parent company of the state-owned construction group is among the top 40 in ENR's 2023 ranking of the world's largest contractors. Under the terms of the agreement, the tw ...

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ: SQFT; SQFTP; SQFTW) ("Presidio" or the "Company"), an internally managed, diversified real estate investment trust ("REIT"), has announced that Conduit Pharmaceuticals Inc. (NASDAQ: CDT, CDTTW) ("Conduit"), of which the Company owns approximately 6.3%, is expected to be added to the Russell 2000 Index effective at the open of US equity markets on Monday, July 1, 2024, as part of the annual reconstitution of the Russell stock ...

CDT, headquartered in Shenzhen, China, is a leading national player in China's waste treatment sector that designs, develops, manufactures, sells, installs, operates and maintains sewage treatment systems and provides sewage treatment services in China, and is dedicated to promoting sustainable development through innovative solutions. Founded by pioneers in waste treatment, CDT aims to advance next-generation technologies that directly address environmental challenges and promote sustainable solutions. CDT ...